ArticlePloS one2025

Daraxonrasib, a pan-RAS inhibitor, selectively inhibits osteosarcomas with activated KRAS by halting AKT signaling and matrix metalloprotease activity.

Okkeun Jung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.